{"filings":[{"id":890759,"accession_number":"0001193805-26-000770","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2026-06-05T21:20:32+00:00","items":["5.07"],"status":"ready","headline":"Arcturus Therapeutics shareholders elect all eight director nominees, approve say-on-pay, and ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees (Farrell, Payne, Barlow, Holmes, Marquet, Marantz, Markels, Slaoui) elected with over 15M votes each.","Non-binding advisory say-on-pay approved: 15.25M for, 327,647 against, 176,375 abstain.","Ratification of Deloitte as independent auditor for 2026 approved: 21.38M for, 46,823 against, 10,349 abstain.","Quorum of 21.44M shares present out of 28.42M shares entitled to vote.","All proposals passed with no significant opposition; no other business transacted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95298,"accession_number":"0001193805-26-000573","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Arcturus Q1 net loss widens to $27M; appoints Dennis Mulroy as CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.0M ($0.95/diluted share), compared to $14.1M loss ($0.52/share) in Q1 2025.","Total operating expenses fell to $31.0M from $46.2M; revenue down $27.3M due to pivot from infectious disease.","Cash and equivalents $213.4M, runway beyond Q2 2028. Cash decreased $19.4M from Dec 2025.","ARCT-032 CF Phase 2 study enrollment initiated; ARCT-810 OTC deficiency gets FDA clarity for pivotal pediatric path.","Dennis Mulroy appointed CFO effective May 1, 2026; base salary $520k, options for 100k shares."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":2061000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108251,"accession_number":"0001193805-26-000214","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus FY2025 net loss narrows to $65.8M; revenue falls 46% to $82M; CF program advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $29.1M ($1.03/shr) vs $30.0M loss prior year; FY net loss $65.8M ($2.40/shr) vs $80.9M.","Revenue Q4 $7.2M, FY $82.0M, down $70.3M YoY due to lower CSL collaboration milestones and supply activity.","Cash $232.8M at Dec 31, 2025; cash runway extended into Q2 2028.","ARCT-032 (CF) third cohort (15 mg, 28 days) safe; 12-week Phase 2 study to start H1 2026.","KOSTAIVE COVID-19 vaccine granted UK MHRA approval in Jan 2026; BARDA pandemic flu vaccine shows durable immune response."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124689,"accession_number":"0001193805-25-001734","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Andy Sassine to depart Dec 31, 2025; Controller Joe Roberts named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Andy Sassine and Arcturus mutually agreed to end employment effective Dec 31, 2025; he also resigned from the Board.","Sassine receives severance: 12 months base salary ($572,000), bonus tied to CEO's 2025 bonus, 18 months COBRA, and full acceleration of 134,689 unvested stock options with 24-month exercise period.","Joe Roberts, company Controller since March 2024, appointed interim principal financial and accounting officer; base salary $219,580, 20% target bonus.","Board size reduced from nine to eight members effective immediately upon Sassine's resignation.","Separation Agreement includes non-disparagement, standard release, and revocation period; severance contingent on release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124688,"accession_number":"0001193805-25-001555","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Therapeutics Reports Q3 2025 Net Loss of $13.5M, Progresses ARCT-032 and ARCT-810 Programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue was $17.2M, down $24.5M from prior year; net loss $13.5M ($0.49 per share) vs $6.9M loss in Q3 2024.","ARCT-032 Phase 2 interim data: inhaled 10mg daily over 28 days well tolerated; mucus burden reduced in 4 of 6 Class I CF adults per HRCT scans.","Company plans a 12-week safety and efficacy study of ARCT-032 in up to 20 CF participants starting H1 2026.","FDA changes delayed U.S. BLA filing for KOSTAIVE indefinitely; additional cost reductions planned in Q4 2025 to extend cash runway into 2028.","ARCT-2304 pandemic flu vaccine candidate induced humoral immune response after single dose at all tested levels, supporting further development."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":74835000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124687,"accession_number":"0001193805-25-001499","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Arcturus reports ARCT-032 CF interim data showing mucus reduction; KOSTAIVE BLA submission delayed by FDA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARCT-032 Phase 2 interim: generally safe/tolerated; 4 of 6 Class I CF patients showed mucus plug/volume reduction after 28 days (10 mg).","FDA requested delay of KOSTAIVE BLA submission (Sep 5), then required additional clinical endpoint efficacy study per updated COVID-19 framework.","CSL Seqirus submitted KOSTAIVE MAA to UK MHRA in June 2025; approval expected Q1 2026, but not assured.","Company filed lawsuit Sep 23, 2025 against AbbVie and Capstan Therapeutics for trade secret misappropriation and breach of contract.","12-week safety/efficacy study of ARCT-032 in up to 20 CF participants planned to start first half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141381,"accession_number":"0001193805-25-001368","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Meiji Seika Pharma launches two-dose vial of KOSTAIVE (sa-mRNA COVID-19 vaccine) in Japan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New two-dose vial presentation of KOSTAIVE launched in Japan on September 26, 2025.","Vaccine targets SARS-CoV-2 Omicron sublineage JN.1 variant XEC.","Non-clinical studies show neutralizing antibodies against XEC, LP.8.1, XFG, NB.1.8.1 variants.","Manufacturing and marketing approval granted August 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141380,"accession_number":"0001193805-25-001247","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Meiji Seika Pharma receives Japan approval for two-dose vial of KOSTAIVE® COVID-19 vaccine","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Approval granted August 28, 2025 for new two-dose vial presentation of KOSTAIVE® (ARCT-2301) in Japan.","Vaccine targets SARS-CoV-2 Omicron sub lineage JN.1 variant XEC; induces neutralizing antibodies against multiple variants.","Meiji Seika Pharma plans to begin supply of the new presentation starting late September 2025.","Non-clinical data shows neutralizing antibodies against JN.1, XEC, LP.8.1, XFG, and NB.1.8.1 variants.","Distribution in Japan is under a prior agreement between Meiji and CSL Seqirus, partner of Arcturus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141379,"accession_number":"0001193805-25-001175","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q2 revenue $28.3M (-43% YoY); net loss narrows to $9.2M; CF data due Sep","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell 43% YoY to $28.3M, driven by lower CSL collaboration activity and KOSTAIVE amortization.","Net loss improved to $9.2M ($0.34 loss per share) from $17.2M loss in Q2 2024.","Operating expenses dropped to $39.9M from $71.0M, mainly on lower KOSTAIVE and flu program costs.","Cash and restricted cash $253.4M, extended runway into 2028.","ARCT-032 CF Phase 2 interim data for 9 participants due Sep 2025; KOSTAIVE UK MAA decision expected Sep 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":57683000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159197,"accession_number":"0001193805-25-000946","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Arcturus ARCT-810 Phase 2 interim: glutamine normalized, ureagenesis improved (p=0.026)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Combined Phase 2 data show glutamine significantly reduced (p=0.0055); levels normalized after 3 doses in US study.","15N-ureagenesis function (RUF) increased from 29.0% baseline to 43.7% at day 28 post-fifth dose (p=0.026).","Ammonia remained stable and within normal range in both studies; one hyperammonemia event on placebo.","ARCT-810 safe and well tolerated across Phase 1/2 with no serious infusion reactions on optimized 3-hour regimen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159196,"accession_number":"0001193805-25-000820","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Arcturus shareholders elect all 9 director nominees, approve say-on-pay, ratify Deloitte","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; votes ranged from 18,555,174 (Dr. Holmes) to 19,059,965 (Dr. Slaoui).","Say-on-pay resolution approved: 18,472,131 for, 586,006 against, 64,724 abstain, 2,883,662 broker non-votes.","Ratification of Deloitte & Touche as FY2025 auditor passed: 21,971,168 for, 30,589 against, 4,767 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159195,"accession_number":"0001193805-25-000630","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q1 net loss narrows to $14.1M; cash runway extends into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.1M ($0.52/diluted share) vs $26.8M ($1.00) a year ago; revenue $29.4M down 23% YoY.","Cash, equivalents and restricted cash $273.8M at March 31, 2025; runway extended into 2028 via resource re-allocation.","Received initial EU approval milestone payment from CSL Seqirus for KOSTAIVE COVID-19 vaccine.","ARCT-032 (CF) Phase 2 interim data from first two cohorts expected mid-2025; enrollment to complete by year-end.","ARCT-810 (OTC) Phase 2 interim data expected Q2 2025; FDA Fast Track granted for H5N1 vaccine ARCT-2304."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":29382000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177645,"accession_number":"0001193805-25-000275","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q4 net loss widens to $30M; KOSTAIVE EC approved, Phase 2 data due Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $30.0M ($1.11/share) vs $11.7M ($0.44) in Q4 2023; revenue down $8.1M to $22.8M.","Full year 2024 revenue $152.3M (down $14.5M YoY); net loss $80.9M ($3.00/share) vs $29.7M ($1.12).","Cash $293.9M at Dec 31, 2024; runway expected to Q1 2027; CSL reported $28M Arcturus share of KOSTAIVE gross profit.","KOSTAIVE received European Commission approval Feb 2025; US BLA filing anticipated 2025; H5N1 vaccine Phase 1 dosed.","ARCT-032 CF and ARCT-810 OTCD Phase 2 interim data on track for Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194349,"accession_number":"0001193805-24-001318","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q3 net loss narrows to $6.9M; $25M milestone from KOSTAIVE first sale in Japan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $41.7M vs $45.2M YoY, down on lower CSL milestones; net loss $6.9M ($0.26/sh) vs $16.2M ($0.61/sh).","Cash $294.1M; runway extended through Q1 2027. Total $462.1M in upfront and milestone payments from CSL to date.","$25M commercial milestone triggered by first sale of KOSTAIVE in Japan by Meiji Seika Pharma in September.","ARCT-032 CF and ARCT-810 OTC deficiency Phase 2 interim proof-of-concept data expected in first half of 2025.","European CHMP opinion for KOSTAIVE expected December 2024; U.S. BLA filing planned in H1 2025."],"consensus_eps_estimate":-0.8397,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":129544000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210689,"accession_number":"0001193805-24-001023","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Arcturus posts updated corporate presentation; details not disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation posted on company website on August 13, 2024.","Presentation content not available in filing; no specific numbers or events reported.","No material changes disclosed in the filing itself."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210688,"accession_number":"0001193805-24-000990","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q2 revenue $49.9M, net loss $17.2M; pipeline advances, Kostaive launch on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $49.9M, up $39.4M YoY from $10.5M, driven by CSL collaboration revenue.","Net loss $17.2M ($0.64 per share) improved from $52.6M loss in Q2 2023.","Cash $317.2M; cash runway extends through Q1 2027; $437.1M received from CSL to date.","IND submitted for ARCT-032 Phase 2 cystic fibrosis study; ARCT-810 OTC deficiency interim data expected Q4 2024.","Kostaive on track for Q4 commercial launch in Japan; EMA review ongoing; COVID/flu programs with CSL progressing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":87871000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229057,"accession_number":"0001193805-24-000842","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Arcturus Therapeutics appoints Dr. Moncef Slaoui to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Moncef Slaoui, former Chief Scientific Advisor for Operation Warp Speed, appointed independent director effective June 19, 2024.","Slaoui brings vaccine industry expertise; previously served on boards of Moderna, Lonza, Vaxcyte, and held leadership at GSK.","Slaoui will receive standard non-employee director compensation as described in 2024 proxy statement.","No arrangements or family relationships with other directors/officers; no reportable transactions under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229056,"accession_number":"0001193805-24-000806","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Arcturus stockholders approve 2M share increase to equity incentive plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to 2019 Omnibus Equity Incentive Plan approved: shares increased by 2,000,000 to 10,750,000 total.","All eight director nominees elected (e.g., Peter Farrell, Joseph Payne) to serve until 2025 annual meeting.","Say-on-pay approved with 19,875,930 For, 1,069,592 Against, 58,600 Abstain.","Ratification of Deloitte & Touche LLP as independent auditor for FY 2024 ratified (23,267,449 For)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229055,"accession_number":"0001193805-24-000614","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Q1 2024 revenue $38M, net loss $26.8M; Kostaive on track for Q3 launch, cash runway through FY2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $38.0M (down 53% YoY); net loss $26.8M ($1.00/share) vs net income $50.8M ($1.87) in Q1 2023.","Cash $345.3M; runway extends at least three years to Q1 FY2027; expects future CSL milestones.","Kostaive commercialization on track: initial 4M doses delivery in Q3; European MAA decision expected Q3.","Phase 3 pivotal study for ARCT-2303 (XBB.1.5) initiated; ARCT-2138 flu Phase 1 topline data expected Q3.","ARCT-810 (OTC) and ARCT-032 (CF) data updates on July 1, 2024; JP Morgan engaged to monetize ARCALIS JV stake."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":38012000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229054,"accession_number":"0001193805-24-000505","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Arcturus Therapeutics dismisses EY as auditor, appoints Deloitte; cites material weaknesses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed Ernst & Young as independent auditor effective April 5, 2024.","EY's 2023 report included an adverse opinion on internal controls over financial reporting, citing material weaknesses in ITGCs and cost review controls.","No disagreements between the company and EY on accounting principles or audit scope during fiscal years 2022 and 2023.","Deloitte & Touche appointed as new independent registered public accounting firm for fiscal year ending December 31, 2024.","Decision followed a competitive process; no prior consultations with Deloitte regarding accounting treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247666,"accession_number":"0001193805-24-000392","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Arcturus partner Meiji reports Phase III success for bivalent COVID-19 booster in Japan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bivalent ARCT-2301 (Kostaive) met primary endpoint of non-inferiority vs COMIRNATY bivalent in GMT ratio and SRR difference.","Superiority against Omicron BA.4/5 and Wuhan strain also confirmed in the phase III study in healthy Japanese adults.","No causally-related severe or serious adverse events reported; safety profile supports platform.","Study conducted by Meiji under distribution agreement with CSL Seqirus for Japan market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247663,"accession_number":"0001193805-24-000364","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K/A","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus Therapeutics amends FY2023 results: revenue down $3.2M, net loss wider","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration revenue for FY2023 decreased from $160.9M to $157.7M; Q4 2023 from $28.2M to $25.0M.","Updated net loss: FY2023 $29.7M ($1.12 per share); Q4 2023 $11.7M ($0.44 per share).","Adjustments are non-cash: deferred revenue increased $3.2M, offset by reduction in stockholders' equity.","Cash, equivalents, restricted cash and cash runway unchanged.","Annual Report on Form 10-K for FY2023 filed March 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247665,"accession_number":"0001193805-24-000335","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcturus FY2023 revenue $169.9M, net loss $26.6M; cash runway extended to Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $169.9M (down from $206.0M); net loss $26.6M ($1.00 diluted EPS) vs prior year net income $9.3M ($0.35 EPS).","Q4 2023 revenue $34.0M (down from $160.3M in Q4 2022, which included $200M CSL upfront); Q4 net loss $8.6M ($0.32 diluted EPS).","Cash and equivalents $348.9M; cash runway extended to Q1 2027; total CSL milestones received $396M.","Kostaive (sa-mRNA COVID vaccine) approved in Japan, launch expected in 2024; ARCT-032 Phase 1b interim data expected Q2 2024.","New STARR vaccine discovery programs for Lyme disease and gonorrhea initiated; ARCT-2138 (LUNAR-FLU) Phase 1 study started."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247664,"accession_number":"0001193805-24-000264","cik":1768224,"company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arcturus Therapeutics controller resigns effective March 15, 2024; assistant controller promoted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith C. Kummerfeld, SVP of Finance and Corporate Controller, resigns effective March 15, 2024 to pursue another opportunity.","Joseph Roberts, formerly Assistant Controller, promoted to Controller of the Company.","Resignation is not due to any disagreement with the Company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":225537047.81201044,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}